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ttp://dx.doi.org/10.1016/j.ajpath.2013.02.025Inﬂammation stimulates new lymphatic vessel growth (inﬂammatory lymphangiogenesis). One key
question is how recurrent inﬂammation, a common clinical condition, regulates lymphatic vessel
remodeling. We show here that recurrent inﬂammation accelerated the development a functional
lymphatic vessel network. This observation suggests a novel program of lymphangiogenesis and
identiﬁes a property of lymphatic vessel memory in response to recurrent inﬂammation. A brief episode
of initial inﬂammation regressed lymphatic vessels, and a signiﬁcant increase in CD11bþ macrophages
were associated with the development of lymphatic vessel memory. These vessels had major differences
in the structure and the spatial distribution of specialized lymphatic vessel features. Surprisingly, we
found that the lymphatic vessel memory response did not depend on the vascular endothelial growth
factor C or A pathway, indicating that different molecular pathways regulate inﬂammatory lym-
phangiogenesis and lymphatic vessel memory. These ﬁndings uncover a priming mechanism to facilitate
a rapid lymphatic vessel memory response: a potential important component of peripheral host defense.
(Am J Pathol 2013, 182: 2418e2428; http://dx.doi.org/10.1016/j.ajpath.2013.02.025)Supported by the State of Nebraska Tobacco Settlement and the NIH:
National Center for Research Resources grant 5P20RR018788-09 and the
National Institute of General Medical Sciences grant 8 P20 GM103471-09,
and grant R01EY021571. This investigation is solely the responsibility of
the authors and does not necessarily represent the ofﬁcial views of the
National Institute for General Medical Science or NIH.The lymphatic vasculature is one component of the inﬂam-
matory response that is remarkably understudied. The lym-
phatic system can be broadly classiﬁed into the lymphoid
tissue (tonsils, lymph nodes, and spleen) and the conduit
system or lymphatic vasculature. The focus of these studies
is the lymphatic capillaries which literally are the most
peripheral extension of the immune system and reside inti-
mately in the diseased tissue. Aside from the classic functions
of the lymphatic vasculature described many years ago
(transport of extracellular ﬂuid, cells, antigens, and lipid),
surprisingly little is known about the normal physiology of
this system and how it regulates inﬂammation and wound
recovery. Multiple lines of evidence have shown that the
lymphatic vasculature proliferates in response to inﬂamma-
tory conditions, suggesting an active, perhaps essential, role
during the inﬂammatory response.1e6 Inﬂammatory lym-
phangiogenesis is thought to be a physiological mechanism
that develops to meet the increased demands of ﬂuid, antigen,
and cellular transport during an inﬂammatory response. New
lymphatic vessel growth has been associated with beneﬁcial
effects in several different preclinical models of acute or
chronic inﬂammatory disease.3,7e9 It is well recognized thatstigative Pathology.
.vascular endothelial growth factor (VEGF)-C-VEGF
receptor (VEGFR)-3 and VEGF-A-VEGFR-2 pathways are
important in inﬂammatory lymphangiogenesis.10 The most
accepted model of inﬂammatory lymphangiogenesis is that
vessels sprout and elongate from pre-existing lymphatic
vessels. In contrast, is some evidence is available that
circulating endothelial progenitors or macrophages differ-
entiate into lymphatic endothelial cells to comprise newly
synthesized lymphatic vessels.11,12
Clinically, two general outcomes occur after an initial
episode of inﬂammatory disease: wound recovery or
recurrent inﬂammation. We developed a mouse model of
wound recovery and recurrent inﬂammation to simulate
these clinical outcomes and to study the lymphatic vascu-
lature during these conditions. We recently demonstrated
that lymphatic vessel regression developed during wound
Figure 1 Schematic of the corneal model of wound recovery and
recurrent inﬂammation. Initial inﬂammation was induced by suture place-
ment at day 0. Wound recovery was studied 14 days after suture removal.
Recurrent inﬂammation was induced by placement of a subsequent suture.
Lymphatic Vessel Memoryrecovery in the cornea.13 Fragmented lymphatic vessels that
persisted over time were visualized in wound recovery
conditions.
In contrast to wound recovery, recurrent inﬂammation is
a common clinical outcome after an initial episode of inﬂam-
mation. We studied the effects of recurrent inﬂammation in
corneal tissue recovered from an initial inﬂammatory response.
This approach is different from earlier studies in that it features
wound recovery followed by recurrent inﬂammation rather
than an acute or chronic unrelenting pathogen or tumor-based
inﬂammatory stimuli.3,4,7,14 We induced recurrent inﬂamma-
tion in recovered corneal tissue by placing a subsequent suture
in the cornea (re-suturing). Here, we show that one feature of
recurrent inﬂammation was the accelerated localized devel-
opment of a functional lymphatic vessel network. The rapid
kinetics and memory response were reminiscent of an immu-
nological memory response; for this reason we describe this
process as lymphatic vessel memory. This response appeared
to stimulate the anastomosis of fragmented lymphatic vessels.
Unlike inﬂammatory lymphangiogenesis induced by initial
inﬂammation, we showed that lymphatic vessel memory
was independent of the VEGF-C and VEGF-A pathways.Figure 2 Corneal wound recovery and recurrent inﬂammation. Placement of
recurrent inﬂammation. Anterior globe images were obtained by thin-section H&E
(D) corneas. E and F: Corneal thickness and the number of MHC class II-positive cel
individual mice. Dot plots and means  SD are shown. The data are representat
Brackets indicate statistical signiﬁcance P < 0.05. Original magniﬁcation: 100
The American Journal of Pathology - ajp.amjpathol.orgThus, these studies reveal a novel program of lymphatic vessel
memory.
Materials and Methods
Mouse Model of Recurrent Corneal Inﬂammation
All animal protocols were approved by Boys Town National
Research Hospital Institutional Animal Care and Use
Committee in accordance with NIH guidelines. 129/SV
mice were purchased from Charles River (Wilmington,
MA). Groups of six to eight sex-matched 129/SV mice aged
6 to 10 weeks were used in the experimental studies.
Corneal sutures were placed to induce initial inﬂammation.
Wound recovery was stimulated by suture removal followed
by a 14-day period. A subsequent suture was placed in
wound recovered cornea to induce recurrent inﬂammation.
Surgical techniques, tissue ﬁxation conditions, antibodies
for immunoﬂuorescence, and H&E staining were described
previously.13 Twenty-micron sections were cut from frozen
eyes and mounted on glass slides. Corneal thickness was
measured in the center of the cornea with the use of ImageJ
(NIH, Bethesda, MD). We quantiﬁed inﬁltrating major
histocompatibility complex (MHC) class II-positive leuko-
cytes by counting the number of MHC class II-positive cells
in the center corneal ﬁeld at 200.
Visualization and Morphometric Analysis of Corneal
Lymphatic Vessels
These techniques were described previously.13 Brieﬂy,
we recorded immunoﬂuorescence images from unsutureda subsequent suture (re-sutured) in wound recovered cornea stimulated
staining of unsutured (A), sutured (B), 14-day recovered (C), and re-sutured
ls were increased in sutured and re-sutured cornea. Dots represent data from
ive of two independent experiments. Asterisk denotes the control group.
(AeD).
2419
Figure 3 The time course and structural characteristics of lymphatic vessel memory during recurrent inﬂammation. The time course of inﬂammatory
lymphangiogenesis was visualized in healthy unsutured cornea (A) or corneas with sutures placed for 1 (B), 3 (C), or 7 (D) days. Corneal recovery and
lymphatic vessel regression was induced in other groups of mice (E). Accelerated lymphangiogenesis was visualized in recovered corneas with recurrent
inﬂammation induced by a subsequent suture placement for 1 (F), 3 (G), or 7 (H) days. These vessels displayed complex distal sprouting that inosculated to
form sheet-like structures (arrowhead, H), sprout suppression proximally (arrow, H), and little new limbal sprouting. Scale bar Z 100 mm. An increase in
lymphatic vessel density and distal tip sprouting were identiﬁed in recurrent inﬂammation. I: The number of lymphatic vessel bulbous tips and fragments per
corneal ﬁeld decreased during recurrent inﬂammation. Dots represent data from individual mice. Dot plots and means  SD are shown. Data from more than
four independent experiments with similar results is shown. D, days.
Kelley et al(noninﬂamed), sutured (initial inﬂammation), suture removed
(wound recovered), and re-sutured (recurrent inﬂammation)
corneas with the use of a Zeiss Axio Imager A.1 microscope
(for epiﬂuoresence) or a Zeiss LSM510 META confocal
microscope. For each corneal epiﬂuorescence image, we
overlaid a customized rectangular grid adjacent to the
constitutive limbal lymphatic vessels. The grid consisted
of 250 square boxes. Each box measured 115 mm2. For
lymphatic density measurements, we counted the number of
grid squares occupied by a lymphatic vessel wall, lumen, or
sprout. We expressed this data as number of occupied grid
squares (relative area)  SD. We quantiﬁed the number of
lymphatic vessel sprouts, bulbous termini, or fragments
within the grid. We deﬁned a vessel sprout as a terminal
conical projection with a length of at least 10 mm and bulbous
termini with a rounded clubbed-shape. Data for lymphatic
vessel plexus size were acquired from stacked confocal
microscopy data (400). We calculated the difference in
microns between the superior and inferior z dimension planes
in which the lymphatic vessels positive for lymphatic vessel
endothelial hyaluronic acid receptor (LYVE)-1 were detected
in corneal tissue with initial or recurrent inﬂammation.2420Quantitative Analysis of MHC Class II-Positive Cells or
CD11bþ Macrophages in the Cornea and Lymphatic
Vessels
These techniques were described in detail previously.13
Whole mount cornea was immunostained with antibodies
to LYVE-1, MHC class II, or CD11b (clone M1/70; BD
Pharmingen, San Jose, CA) and the appropriate secondary
antibodies. We counted the number of MHC class II or
CD11bþ cells in corneal hemisections with the use of
confocal microscopy. We quantiﬁed MHC class II-positive
cells in contact or within LYVE-1-positive primary or
secondary lymphatic vessels in projected images at 400.
Quantitative RT-PCR
RNA was isolated from whole mouse unsutured cornea or
corneas with initial inﬂammation, wound recovery, or recur-
rent inﬂammation conditions with the use of TRIzol Reagent
per manufacturer instructions (Invitrogen, Grand Island, NY).
Three or four mouse corneas were studied independently in
each condition.CornealRNA(300ng)was reverse transcribedajp.amjpathol.org - The American Journal of Pathology
Figure 4 Recurrent inﬂammation stimulated unusual, but not uncommon, lymphatic vessel structure. Lymphatic vessels were stained with antibodies to
LYVE-1 (red) or CD31 (green). Lymphatic vessel fragments were visualized with intense LYVE-1 staining and expression of nonpolarized ﬁlopodia (A) or features
of bulbous termini and sprout formation (B) in corneas with recurrent inﬂammation. Some distal sprouts had complex abundant ﬁlopodia and sprout
development along stalk structures (C). MHC class II-positive cells (white) were visualized within bulbous termini (arrowhead) and in some cases adjacent to
a sprouting vessel (D). AeD: Images were obtained with confocal microscopy. E: A statistically signiﬁcant increase was detected in the z dimension (corneal
depth) in secondary lymphangiogenesis. Dots represent data from individual mice. Dot plots and means  SD are shown. Asterisk denotes the control group.
Brackets indicate statistical signiﬁcance P < 0.05. Scale bar Z 50 mm (AeD).
Lymphatic Vessel Memorywith Superscript III First Strand Synthesis System (Invi-
trogen). cDNA was ampliﬁed in triplicate reactions with the
use of TaqMan Gene Expression Master Mix and TaqMan-
based probes and primers (Applied Biosystems, Grand Island,
NY). Data were normalized to glyceraldehyde 3-phosphate
dehydrogenase. Mean fold induction of mRNA levels relative
to unsutured cornea, using three replicates, was shown.
VEGFR-2-Fc and VEGFR-3-Fc Decoy Receptor Studies
After induction of initial or recurrent inﬂammation, Fc
control protein, VEGFR-2-Fc and VEGFR-3-Fc, or VEGFR-
3-Fc alone (R& D Systems, Minneapolis, MN) was injected
into the subconjunctival space at 0, 2, and 4 days. Approxi-
mately 10 mL of 100 ng/mL decoy receptor or Fc control
protein suspended in PBSþ 0.1% bovine serum albumin, pH
7.4 were injected. After 7 days, corneal tissue was harvested,
and the lymphatic vasculature was visualized and quantiﬁed.
Statistical Analysis
Dot plots representing data from individual corneas were
shown in all ﬁgures. The broad horizontal bars were the
means and the two-way error bars show means  SD. A
one-way analysis of variance was used followed by Dunnett
multiple comparison test to compare the control group,
denoted with asterisk, with the experimental groups. A two-
tailed t-test was used to compare studies with two groups.
Brackets between groups show a P value < 0.05.
Results
Corneal Model of Recurrent Inﬂammation
The present study was designed to investigate lymphatic
vessel remodeling during recurrent inﬂammation. WeThe American Journal of Pathology - ajp.amjpathol.orgstimulated recurrent inﬂammation by re-suturing wound
recovered cornea (Figure 1). Increased corneal thickness,
inﬁltrating inﬂammatory cells, and inﬂammatory cytokines
(IL-6 and IL-1) were quantiﬁed in resutured cornea (Figure 2,
AeF) (data not shown). These ﬁndings were consistent with
a recurrent inﬂammatory response.
Lymphatic Vessel Memory
Using whole corneal mounts and immunoﬂuorescence
microscopy, we demonstrated an accelerated process of lym-
phangiogenesis during a recurrent inﬂammatory response.
Initial inﬂammation induced inﬂammatory lymphangio-
genesis that sprouted from the pre-existing limbal lymphatic
vessel and was readily visualized after 3 days (Figure 3,
AeD). After a 14-day period of wound recovery and
lymphatic vessel regression, recurrent inﬂammation induced
the alignment of regressed lymphatic vessels at day 1.
A mature-appearing lymphatic vessel network was visualized
at day 3 and continued to develop until day 7 (Figure 3, EeH).
One interpretation of these results is that recurrent inﬂamma-
tion reactivated regressed lymphatic vessels to quickly
assemble a lymphatic vessel network. The kinetics of this
response were rapid and reminiscent of immunological
memory response. Hence, we described this response as
lymphatic vessel memory. Compared with inﬂammatory
lymphangiogenesis stimulated with initial inﬂammation, the
lymphatic vessel memory response was dense and had
a number of other distinct structural features. A similar
number of sprouts were quantiﬁed in both conditions;
however, the zone of sprouting was more distal (Figure 3I).
Some of the memory vessels had a complex bizarre structure
and appeared to form a syncytium with frequent anastomosis
that formed loop structures. We visualized an oak leaf pattern
of LYVE-1 staining in lymphatic memory vessel stalks that2421
Figure 5 A brief episode of initial inﬂammation and the presence of lymphatic vessels were associatedwith lymphatic vessel memory. Regressed lymphatic vessels
werevisualized in conditions ofwoundrecoveryafter initial inﬂammation, in somecases for 1day (A), andall cases for 3 (B), 5 (C), or 7 (D) days.Recurrent inﬂammation
was stimulated in similarly treated groups of mice. Some mice with initial inﬂammation for 1 day (E) and all mice with initial inﬂammation for 3 to 7 days (FeH)
developeda lymphatic vesselmemory response. Scale barZ100mm. I: Similar increases in lymphatic vesselmemorydensitywerevisualized inmice stimulatedwith 3 to
7 days of initial inﬂammation. Dots represent data from individual mice. Dot plots and means SD are shown. Data shown was representative from two independent
experiments with similar results. Black squares represent wound recovery and white squares represent recurrent inﬂammation after wound recovery. D, days.
Kelley et alextended from the limbal lymphatic vessels. This staining
pattern was consistent with mature constitutively expressed
lymphatic vessels.15 We quantiﬁed bulbous tips rather than
lymphatic sprouts proximally and observed few new sprouts
emerging from the limbus (Figure 3, GeI). Although most
lymphatic fragments seemed to anastomose and form the
secondary lymphangiogenic network, some lymphaticFigure 6 Lymphatic vessel memory was spatially restricted after an initial inﬂa
half of the cornea with two sutures for 7 days. After suture removal and wound recov
placed in the temporal hemisphere (B). C: A statically signiﬁcant difference in lymp
data from individual mice. Dot plots and means SD are shown. Data shown was rep
between groups indicate a statistically signiﬁcant difference. Asterisk denotes th
2422fragments persisted within the corneal stroma. These frag-
ments had the unusual characteristics of nonpolarized ﬁlopo-
dia, intense LYVE-1 expression, and the tendency to
accumulate MHC class II leukocytes (Figure 4, AeD). Not
only was the density (measured in the x and y dimensions)
increased, but also the space occupied by the lymphatic
memory vessels in the z IF increased several times relative tommatory response. Initial inﬂammation was stimulated in the temporal one-
ery, two sutures were placed in the nasal hemisphere (A) and two sutures were
hatic vessel density was observed between the hemispheres. Dots represent
resentative from two independent experiments with similar results. Brackets
e control group. Brackets indicate statistical signiﬁcance P < 0.05.
ajp.amjpathol.org - The American Journal of Pathology
Figure 7 Similar numbers of MHC class II-positive cells were visualized and quantiﬁed in primaryz and secondary lymphatic vessels. Similar numbers of
MHC class II-positive cells were visualized interfaced or within primary lymphatic vessels (A and B) and secondary lymphatic vessels (C and D). B and D: Shown
are orthogonal images of a single z dimension image that shows LYVE-1-positive lymphatic vessels (red) around MHC class II-positive leukocytes (green), top
and far right panels. Similar numbers of MHC class II-positive cells were quantiﬁed in corneal tissue with primary or secondary lymphangiogenesis (E) and
interfaced or within primary or secondary lymphatic vessels (F). E and F: Dots represent data from individual mice. Dot plots and means  SD are shown. The
data are representative of two independent experiments. Asterisk denotes the control group. Brackets indicate statistical signiﬁcance P < 0.05.
Lymphatic Vessel Memoryinﬂammatory lymphangiogenesis (Figure 4E). This ﬁnding
suggested that these lymphatic vessels may have increased
exposure to components of the extracellular matrix. These
structural observations distinguished inﬂammatory lym-
phangiogenesis from lymphatic vessel memory responses.
The duration of initial inﬂammation required to stimulate
lymphatic vessel memory was investigated. For these
experiments we varied the duration of initial inﬂammation
(suture placement for 1, 3, 5, or 7 days) and held constant
for the duration of wound recovery (14 days) and recurrent
inﬂammation (7 days). We did not visualize lymphatic
vessels during wound recovery conditions after initial
inﬂammation stimulated by suture placement for 1 day. In
contrast, regressed lymphatic vessels were visualized in
wound recovery conditions after initial inﬂammation stim-
ulated by suture placement for 3, 5, or 7 days (Figure 5,
AeD). We induced recurrent inﬂammation in similarly
treated groups of mice. Initial inﬂammation for 1 day was
not adequate to stimulate lymphatic vessel memory.
Lymphatic vessel memory responses were visualized and
quantiﬁed in mice with initial inﬂammation for 3, 5, and 7
days (Figure 5, EeI). The density and structural character-
istics of the lymphatic vessel memory responses were
remarkably similar, despite the variable duration of the
initial inﬂammation episode.
We investigated whether lymphatic vessel memory was
a spatially restricted or global corneal property after an
initial inﬂammatory response. Initial inﬂammation was
stimulated by placing two sutures for 7 days in the temporal
one-half of the cornea. After wound recovery we placed two
black sutures in the temporal corneal hemisphere (previ-
ously inﬂamed) and two blue sutures in the nasal hemi-
sphere. The different color sutures allowed us to distinguishThe American Journal of Pathology - ajp.amjpathol.orgbetween the hemispheres during the analysis. Inﬂammatory
lymphangiogenesis was visualized and quantiﬁed in the
corneal nasal hemisphere with an initial suture. Dense
structurally distinct responses consistent with a lymphatic
vessel memory response were detected in the temporal
hemispheres with initial suture-induced inﬂammation. A
statically signiﬁcant difference was observed in lymphatic
vessel density between the hemispheres (Figure 6, AeC).
These ﬁndings indicated a lymphatic vessel memory prop-
erty of spatial restriction.
Leukocyte trafﬁcking is one well-accepted function of
lymphatic vessels.16,17 We visualized and quantiﬁed similar
numbers of MHC class II-positive cells within the corneal
stroma, and similar numbers of MHC class II-positive cells
were visualized interfacing or migrating within lymphatic
vessels stimulated with initial or recurrent inﬂammation
(Figure 7, AeF). This data indicated that lymphatic memory
vessels function to trafﬁc MHC class II-positive cells.
Candidate Cellular and Molecular Mechanisms that
Regulate Lymphatic Vessel Memory
The rapid expansion of a functional lymphatic vessel
memory response during recurrent inﬂammation suggested
that recovered tissue was endowed with a priming or
memory mechanism to facilitate these processes. CD11bþ
macrophages have been described to regulate inﬂammatory
lymphangiogenesis. The two most well-accepted mecha-
nisms are nonexclusive. Several lines of evidence have
indicated that the macrophages express VEGF-C, a well-
characterized lymphangiogenic growth factor. Macro-
phages have been reported to differentiate into lymphatic
endothelial cells. We used three-color immunoﬂuorescent2423
Figure 8 CD11bþ macrophages accumulation during corneal inﬂammation. Three-color confocal immunoﬂuorescence microscopy was performed to
visualize and quantify CD11bþ macrophages (green), lymphatic vessels (red), and MHC class II-positive cells (white) in conditions of initial inﬂammation
(suture placement for 7 days; A), wound recovery for 14 days (B), or recurrent inﬂammation for 1 (C) or 3 (D) days. Increased numbers of CD11bþ macrophages
were detected in conditions of initial or recurrent inﬂammation, and few cells were visualized in conditions of wound recovery (E). Compared with CD11bþ cells
substantially fewer MHC class II cells were quantiﬁed (F). Increased numbers of MHC class II-positive cells were quantiﬁed in initial inﬂammatory conditions,
and similar numbers were detected during wound recovery and recurrent inﬂammation. Little to no MHC class II expression was detected in the CD11bþ
macrophage population. Unlike MHC class II-positive cells, CD11bþ cells were not visualized trafﬁcking within the lymphatic vessels in any conditions. E and F:
Dot plots and means  SD are shown. The data are representative of two independent experiments. Asterisk denotes the control group. Brackets indicate
statistical signiﬁcance P < 0.05.
Kelley et alconfocal microscopy to visualize and localize CD11bþ
macrophages during corneal wound recovery and recurrent
inﬂammation. We visualized and quantiﬁed a signiﬁcant
increase of CD11bþ macrophages during initial inﬂamma-
tion. Few CD11bþ macrophages were identiﬁed in condi-
tions of wound recovery, and this cell population increased
during recurrent inﬂammation (Figure 8, AeE). The abso-
lute number of CD11bþ macrophages was greater than the
MHC class II population (Figure 8F), and few if any
CD11bþ macrophages were MHC class II positive. Unlike
the MHC class II population, the CD11bþ cells were not
detected within the lumen of the lymphatic vessels.
A number of genes known to be involved in developmental
or inﬂammatory lymphangiogenesiswere examined (Figure 9).
mRNA levels of the prolymphangiogenic cytokines, VEGF-C
and VEGF-A, increased during wound recovery and recurrent
inﬂammation.VEGFR-3mRNA levels did not change.mRNA
levels of the prolymphangiogenic protease matrix metal-
loprotease 10 were increased during inﬂammatory condi-
tions,18 and levels returned to baseline duringwound recovery.
The level of sex determining regionY-box18mRNA increased2424during recurrent inﬂammation. Prospero homeobox 1 and
LYVE1 mRNA levels did not change. Chicken ovalbumin
upstream promoter transcription factor 2 mRNA levels were
decreased during initial and recurrent inﬂammation. Notch
homolog 1 mRNA levels were decreased in conditions of
wound recovery and recurrent inﬂammation, and no signiﬁcant
changes were detected in Delta-like ligand 4. These results
identiﬁed VEGF-A and VEGF-C as candidate factors to
facilitate the lymphatic vessel memory response.
Lymphatic Vessel Memory Is Independent of VEGF-C
and VEGF-A
It is well established that VEGF-C and VEGF-A regulate
lymphangiogenesis. We explored whether lymphatic vessel
memory involved the VEGF-C and VEGF-A pathways with
the use of VEGFR-2-Fc (R2) and VEGFR-3-Fc (R3) decoy
receptors. We stimulated inﬂammatory lymphangiogenesis
with initial inﬂammation and treated mice with serial sub-
conjunctival injection of control Fc protein, a combination
of R2R3 decoy receptors, or R3 decoy receptor alone.ajp.amjpathol.org - The American Journal of Pathology
Figure 9 Increased mRNA levels of VEGF-C and VEGF-A during wound
recovery and recurrent inﬂammation. VEGF-C, VEGF-A, VEGFR-3, matrix
metalloprotease (MMP)-10, sex determining region Y-box 18 (Sox-18),
prospero homeobox 1 (Prox1), LYVE1, chicken ovalbumin upstream promoter
transcription factor 2 (CoupTFII), Notch homolog 1 (Notch 1), and Delta-like
ligand 4 (DLL4) mRNA levels were quantiﬁed in unsutured corneal tissue and
conditions of initial inﬂammation, wound recovery, and recurrent inﬂam-
mation. Dots represent data from individual mice. The dot plots and means
SD are mean fold mRNA levels normalized to glyceraldehyde 3-phosphate
dehydrogenase. Asterisk denotes the control group. Brackets indicate
statistical signiﬁcance P < 0.05.
Lymphatic Vessel MemoryWe visualized and quantiﬁed inhibition of inﬂammatory
lymphangiogenesis in groups of mice treated with the R2R3
decoy receptor combination or the R3 decoy receptor alone.
These results were statistically signiﬁcant. We stimulated
lymphatic vessel memory with recurrent inﬂammation and
treated groups of mice with serial subconjunctival injection
of control Fc protein, a combination of R2R3 decoyThe American Journal of Pathology - ajp.amjpathol.orgreceptors, or the R3 decoy receptor alone. No difference was
observed in structural features and density in the lymphatic
vessel memory responses, despite R2R3 and R3 decoy
receptor administration (Figure 10, AeH).
Discussion
The main ﬁnding presented here is that recurrent inﬂamma-
tion stimulated an accelerated structurally distinct program of
lymphangiogenesis that we refer to as lymphatic vessel
memory. We showed that in contrast to inﬂammatory lym-
phangiogenesis, lymphatic vessel memory was not depen-
dent on the VEGF-C or VEGF-A pathway.
Wound Recovery and Lymphatic Vessel Regression
We designed experiments to simulate the two primary clinical
outcomes of inﬂammatory disease: wound recovery or
recurrent inﬂammation. One of the strengths of the corneal
model is the ability to induce and objectively quantify wound
recovery and recurrent inﬂammation. Many pathogen- and
tumor-based models establish chronic unrelenting inﬂam-
matory responses that make it difﬁcult to induce wound
recovery or serial episodes of inﬂammation. We recently
established that lymphatic vessel regression developed during
corneal wound recovery.13 These observations lead us to
consider whether lymphatic vessel regression was reversible.
Recurrent Inﬂammation and Lymphatic Vessel Memory
Here, we show that recurrent inﬂammation stimulated the rapid
development of a functional lymphatic vesselmemory network.
Unlike inﬂammatory lymphangiogenesis, lymphatic vessel
memory was not dependent on the VEGF-C or VEGF-A
pathway. Several models of inﬂammatory lymphangiogenesis
are described: vessel sprouting and stalk elongation from pre-
existing lymphatic vessels,6 transdifferentiation of macro-
phages,11 or the incorporation of circulating endothelial
progenitors.19 Although there may be some common mecha-
nisms, lymphatic vessel memory appears to represent a distinct
type of lymphangiogenesis. The rapid development of the
lymphatic vessel memory response suggested a priming
mechanism that likely developed during initial inﬂammation or
wound recovery. The structure of the lymphatic vessel memory
response is unique. It appears to involve the activation and
anastomosis of regressed lymphatic vessels and mechanisms to
facilitate tip-to-tip guidance, fragment migration, and vessel
fusion, none of which have been described previously. The
speciﬁc role of the CD11bþ macrophages in lymphatic vessel
memory is unclear. Several lines of evidence support a role for
macrophages during inﬂammatory lymphangiogenesis.11,20,21
Here, we show that the number of CD11bþ macrophages
increased signiﬁcantly during initial inﬂammation and inﬂam-
matory lymphangiogenesis, decreased during wound recovery,
and increased dramatically during the lymphatic vesselmemory
response stimulatedby recurrent inﬂammation. Surprisingly, no2425
Figure 10 Lymphatic vessel memory was independent of VEGF-A and VEGF-C pathways. Inﬂammatory lymphangiogenesis stimulated with initial
inﬂammation was visualized after injection of Fc control (A). Inﬂammatory lymphangiogenesis was inhibited after injection of decoy receptors VEGFR-2-Fc and
VEGFR-3-Fc (R2R3) (B) or VEGFR-3-Fc (R3) (C). Similar programs of lymphatic vessel memory were detected in corneas injected with Fc control (E), VEGFR-2-Fc
and VEGFR-3-Fc (F), and VEGFR-3-Fc (G). D and H: Dots represent data from individual mice. The dot plots and means  SD are pooled data from three
independent experiments. Asterisk denotes the control group. Brackets indicate statistical signiﬁcance P < 0.05.
Kelley et aldetectable MHC class II-positive CD11bþ macrophages were
identiﬁed during inﬂammatory conditions. Corneal CD11bþ
macrophages have been described to express low levels of
MHC class II,22 and our results may represent a technologic
limitation of MHC class II detection with the use of whole
mount immunostaining protocols. At least one report has
described that macrophages function to couple blood vessels
during vascular remodeling.23 A similar mechanism may
facilitate lymphatic vessel fragment anastomosis during
a lymphatic vessel memory response. CD11bþ macrophages
have been described to facilitate the resolution of inﬂamma-
tion.24 It remains unclear whether the macrophage population
represents a speciﬁc component of the priming mechanism, an
active participant in the resolution of inﬂammation, or an
essential constituent of the lymphatic vessel memory network.
Features of lymphatic vessel specialization such as
sprouting, bulbous tip formation, and stalk development
are presumably related to lymphatic vessel function. We
observed spatial restriction and spatial regulation of special-
ized lymphatic vessel features during lymphatic vessel
memory responses. For example, the number of lymphatic
vessel sprouts was similar; however, the sprouting was more
distal in lymphatic vessel memory responses than in inﬂam-
matory lymphangiogenesis. Interestingly, few new sprouts
developed from the pre-existing limbal lymphatic vessels, and
we did not visualize lymphatic vessel sprouts close to the
limbal vessels in these conditions. The Notch-Delta pathway
may be involved in lymphatic vessel memory because this
pathway was described to suppress lymphangiogenic sprouts
and to promote tip-to-stalk transformation.25e29 The results of
the RT-qPCR studies show that Delta-like ligand 4 mRNA
levels were similar in corneal wound recovery and recurrent2426inﬂammation and that Notch 1 mRNA levels were decreased
in corneal tissue during wound recovery and recurrent
inﬂammation. Given the number of components and the
complexity of the Notch pathways, a more comprehensive
investigation will be required to determine the precise role of
the Notch pathways in lymphatic vessel memory. Lymphatic
vessels stimulated by recurrent inﬂammation were functional
because they had the capacity to transport MHC class
II-positive leukocytes. Although the mechanisms are not well
appreciated, there is little doubt that leukocyte migration via
the lymphatic vessels contributes to immunity.16,30 Lym-
phatic vessel memory may represent an important peripheral
component of host defense. The rapid assembly of a
secondary lymphatic vessel network may facilitate efﬁcient
antigen and leukocyte transport to regional lymph nodes, sites
of intense immunological activity.
It is unclear whether lymphatic vessel memory is a
process that is unique to the cornea or represents a systemic
process. In both corneal and noncorneal models, lymphatic
vessels have been identiﬁed to persist after the resolution of
the inﬂammatory response.3,4 It is possible that these
persistent lymphatic vessels are conditioned to respond to
recurrent inﬂammation with a memory response.
Lymphatic Vessel Memory Is Independent of VEGF-C
and VEGF-A
Many lines of evidence have indicated a critical role for
VEGF-C and VEGF-A during lymphangiogenesis.10,31e33 We
identiﬁed higher levels of VEGF-C and VEGF-A mRNA in
conditions of wound recovery and recurrent inﬂammation. This
ﬁnding was consistent with a role for these cytokines inajp.amjpathol.org - The American Journal of Pathology
Lymphatic Vessel Memorylymphatic vessel memory. With the use of VEGFR-2 and R3
decoy receptors,we inhibited inﬂammatory lymphangiogenesis
but not lymphatic vessel memory. This ﬁnding suggests that
mechanisms other than the VEGF-A or VEGF-C pathway
regulate lymphatic vesselmemory. Long-lastingVEGFR-2 and
R3 signaling effects or the inability of the decoy receptors to
sequester cytokines in a different microenvironment are two
alternative interpretations of this result. Despite the inhibition of
the VEGF-C and VEGF-A pathways, the limbal lymphatic
vessels persisted in both conditions. This result was similar
to other investigations that described the persistence of
pre-existing lymphatic vessels despite VEGF-C or VEGF-A
inhibition.34,35 Together these ﬁndings support a model of
lymphatic vessel network maturation in which initial in-
ﬂammatory lymphangiogenesis is regulated by VEGF-C or
VEGF-A signals, and lymphatic vessel memory responses are
regulated by different mechanisms.Clinical Signiﬁcance
Many corneal and possibly noncorneal conditions of recur-
rent inﬂammation may involve pathological processes that
stimulate lymphatic vessel memory pathways. Directed
VEGF-C or VEGF-A pathwaymanipulation may not provide
the anticipated clinical beneﬁts because these pathways do
not appear to regulate lymphatic vessel memory. Identiﬁca-
tion of the factors that prime and regulate lymphatic vessel
memory will be important in future studies. Understanding
how lymphatic vessel memory responses regulate recurrent
inﬂammatory disease will shape clinical paradigms and
future medical therapies.References
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